Introduction to the topic "Assessing benefit without considering harm?
Prof. Dr. Ralf Bender
Interpreting poor quality results on adverse events within the framework of systematic reviews using the example of studies on benign prostatic hyperplasia
Dr. Gudio Skipka
Assessing harm within the framework of the benefit assessment of drugs
Dr. Beate Wieseler
Benefit-harm assessment of drugs following authorisation
Dr. Ulrich Hagemann (Federal Institute for Drugs and Medical Devices, BfArM)
Benefit and harm of drugs ? both sides of the coin. Reflections on assessments ?who carries them out, when and how?
Dr. Dr. Norbert Banik (GlaxoSmithKline GmbH & Co. KG)